1. Home
  2. IKNA vs CRT Comparison

IKNA vs CRT Comparison

Compare IKNA & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • CRT
  • Stock Information
  • Founded
  • IKNA 2016
  • CRT 1991
  • Country
  • IKNA United States
  • CRT United States
  • Employees
  • IKNA N/A
  • CRT N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • CRT Oil & Gas Production
  • Sector
  • IKNA Health Care
  • CRT Energy
  • Exchange
  • IKNA Nasdaq
  • CRT Nasdaq
  • Market Cap
  • IKNA 63.7M
  • CRT 65.1M
  • IPO Year
  • IKNA 2021
  • CRT 1992
  • Fundamental
  • Price
  • IKNA $1.43
  • CRT $9.53
  • Analyst Decision
  • IKNA Buy
  • CRT
  • Analyst Count
  • IKNA 2
  • CRT 0
  • Target Price
  • IKNA $13.50
  • CRT N/A
  • AVG Volume (30 Days)
  • IKNA 434.6K
  • CRT 20.0K
  • Earning Date
  • IKNA 07-24-2025
  • CRT 01-01-0001
  • Dividend Yield
  • IKNA N/A
  • CRT 9.35%
  • EPS Growth
  • IKNA N/A
  • CRT N/A
  • EPS
  • IKNA N/A
  • CRT 0.99
  • Revenue
  • IKNA N/A
  • CRT $6,834,116.00
  • Revenue This Year
  • IKNA N/A
  • CRT N/A
  • Revenue Next Year
  • IKNA N/A
  • CRT N/A
  • P/E Ratio
  • IKNA N/A
  • CRT $9.58
  • Revenue Growth
  • IKNA N/A
  • CRT N/A
  • 52 Week Low
  • IKNA $0.97
  • CRT $8.88
  • 52 Week High
  • IKNA $1.94
  • CRT $13.31
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 59.83
  • CRT 39.12
  • Support Level
  • IKNA $1.20
  • CRT $9.41
  • Resistance Level
  • IKNA $1.42
  • CRT $9.86
  • Average True Range (ATR)
  • IKNA 0.08
  • CRT 0.13
  • MACD
  • IKNA 0.00
  • CRT -0.01
  • Stochastic Oscillator
  • IKNA 82.26
  • CRT 26.67

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

Share on Social Networks: